How AI Is Cutting Protocol Amendments and Accelerating Clinical Trials
Clinical trial protocols remain one of the most time-consuming, error-prone, and expensive parts of drug development, driven in large part by the high frequency of protocol amendments. Amendment prevalence rose from 57% in 2016 to 76% in the most recent 2022/2024 wave, with affected protocols now averaging around 3.3 amendments each.
Not every amendment is preventable, but roughly 23% are considered preventable, often caused by drafting inconsistencies, dosing errors, overly restrictive eligibility criteria, or feasibility issues. AI tools can now detect design flaws earlier, evaluate feasibility more accurately, and simulate operational performance before enrollment begins, helping sponsors shorten development cycles and improve overall protocol quality.
Read More
